I期临床-话题@MedSci

#I期临床#

570篇内容 | 7030人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1653201, encodeId=8645165320126, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=拜耳启动Elinzanetant III期临床研发项目OASIS，用于治疗更年期血管舒缩症状, objectType=article, longId=214643, objectId=e3b121464360, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3b121464360, replyNumber=0, likeNumber=0, createdTime=2022-07-03, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3b121464360, moduleTitle=拜耳启动Elinzanetant III期临床研发项目OASIS，用于治疗更年期血管舒缩症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3b121464360)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653146, encodeId=0ed81653146e1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=国药新冠疫苗国内上市申请获受理，III期临床仍在继续, objectType=article, longId=205619, objectId=442220561905, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=442220561905, replyNumber=0, likeNumber=78, createdTime=2021-07-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=442220561905, moduleTitle=国药新冠疫苗国内上市申请获受理，III期临床仍在继续, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=442220561905)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653132, encodeId=b60e16531324b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验, objectType=article, longId=203861, objectId=324020386153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=324020386153, replyNumber=0, likeNumber=57, createdTime=2021-06-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=324020386153, moduleTitle=中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=324020386153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653081, encodeId=d695165308123, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Xerava（eravacycline）治疗复杂腹腔内感染：即将开展中国III期临床试验, objectType=article, longId=200046, objectId=dd8a2000461b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd8a2000461b, replyNumber=0, likeNumber=55, createdTime=2020-12-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd8a2000461b, moduleTitle=Xerava（eravacycline）治疗复杂腹腔内感染：即将开展中国III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd8a2000461b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653161, encodeId=34861653161fb, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=IkT-148009治疗帕金森，I期临床试验已正式开始, objectType=article, longId=207290, objectId=56ba20e290d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56ba20e290d4, replyNumber=0, likeNumber=83, createdTime=2021-11-02, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56ba20e290d4, moduleTitle=IkT-148009治疗帕金森，I期临床试验已正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56ba20e290d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653163, encodeId=143216531632f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=晚期卵巢癌的治疗取得新进展，GEN-1在I / II期临床中取得喜人结果！, objectType=article, longId=207665, objectId=541220e665a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=541220e665a5, replyNumber=0, likeNumber=81, createdTime=2021-11-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=541220e665a5, moduleTitle=晚期卵巢癌的治疗取得新进展，GEN-1在I / II期临床中取得喜人结果！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=541220e665a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653195, encodeId=54d316531958a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Nat Med：严重肥胖和代谢综合征患者的粪便微生物移植II期临床试验 , objectType=article, longId=213880, objectId=451f213880fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=451f213880fd, replyNumber=0, likeNumber=89, createdTime=2022-01-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=451f213880fd, moduleTitle=Nat Med：严重肥胖和代谢综合征患者的粪便微生物移植II期临床试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=451f213880fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653134, encodeId=96431653134d5, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=TC-210治疗难治性间皮素阳性实体瘤：I/II期临床试验取得积极结果, objectType=article, longId=204514, objectId=6550204514fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6550204514fe, replyNumber=0, likeNumber=85, createdTime=2021-01-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6550204514fe, moduleTitle=TC-210治疗难治性间皮素阳性实体瘤：I/II期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6550204514fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653160, encodeId=e040165316095, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验, objectType=article, longId=207256, objectId=1d0f20e25662, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d0f20e25662, replyNumber=0, likeNumber=23, createdTime=2021-07-18, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d0f20e25662, moduleTitle=NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d0f20e25662)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653183, encodeId=dc111653183b3, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：TSLP单抗Tezepelumab治疗严重不受控制哮喘III期临床研究获得成功, objectType=article, longId=211275, objectId=f24b2112e55c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f24b2112e55c, replyNumber=0, likeNumber=63, createdTime=2022-03-16, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f24b2112e55c, moduleTitle=NEJM：TSLP单抗Tezepelumab治疗严重不受控制哮喘III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f24b2112e55c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653138, encodeId=ddb1165313840, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=患者招募：吡咯替尼联合沙利度胺治疗HER2突变型非小细胞肺癌的单臂、开放、前瞻性II期临床研究, objectType=article, longId=204833, objectId=e12e20483351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e12e20483351, replyNumber=0, likeNumber=88, createdTime=2021-08-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e12e20483351, moduleTitle=患者招募：吡咯替尼联合沙利度胺治疗HER2突变型非小细胞肺癌的单臂、开放、前瞻性II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e12e20483351)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653129, encodeId=c901165312902, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=HIV口服“疫苗”时代到来！默沙东口服长效新药开展III期临床, objectType=article, longId=203221, objectId=df78203221cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df78203221cf, replyNumber=0, likeNumber=56, createdTime=2021-04-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df78203221cf, moduleTitle=HIV口服“疫苗”时代到来！默沙东口服长效新药开展III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df78203221cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653097, encodeId=6166165309e1c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=REVTx-99治疗COVID-19：即将开展I期临床研究, objectType=article, longId=201503, objectId=d496201503d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d496201503d9, replyNumber=0, likeNumber=72, createdTime=2021-09-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d496201503d9, moduleTitle=REVTx-99治疗COVID-19：即将开展I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d496201503d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653096, encodeId=a2671653096d5, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=强生新冠疫苗进入III期临床试验，大选前疫苗出炉有望吗？, objectType=article, longId=201486, objectId=14fc201486bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14fc201486bd, replyNumber=0, likeNumber=99, createdTime=2020-12-18, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14fc201486bd, moduleTitle=强生新冠疫苗进入III期临床试验，大选前疫苗出炉有望吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14fc201486bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653073, encodeId=784916530e34e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=以治愈艾滋病为目标！FDA批准美国基因技术公司（AGT）推进HIV治愈计划的I期临床, objectType=article, longId=199302, objectId=2844199302a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2844199302a1, replyNumber=0, likeNumber=72, createdTime=2021-01-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2844199302a1, moduleTitle=以治愈艾滋病为目标！FDA批准美国基因技术公司（AGT）推进HIV治愈计划的I期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2844199302a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653189, encodeId=2b4d1653189c9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：Sotorasib治疗KRASp.G12C突变晚期非小细胞肺癌II期临床数据喜人, objectType=article, longId=212430, objectId=207d212430a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=207d212430a0, replyNumber=0, likeNumber=86, createdTime=2021-06-10, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=207d212430a0, moduleTitle=NEJM：Sotorasib治疗KRASp.G12C突变晚期非小细胞肺癌II期临床数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=207d212430a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653157, encodeId=4e8c165315eac, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=强生单剂新冠疫苗综合有效率达66%，康希诺继续推进Ad5-nCoV的III期临床试验, objectType=article, longId=206565, objectId=0ffe20656522, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ffe20656522, replyNumber=0, likeNumber=146, createdTime=2021-02-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ffe20656522, moduleTitle=强生单剂新冠疫苗综合有效率达66%，康希诺继续推进Ad5-nCoV的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ffe20656522)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653070, encodeId=aeea16530e030, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, objectType=article, longId=199268, objectId=b8ff199268d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ff199268d0, replyNumber=0, likeNumber=69, createdTime=2021-03-16, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ff199268d0, moduleTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ff199268d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653084, encodeId=73bf1653084cf, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet：Vosoritide治疗儿童软骨发育不良III期临床获得成功, objectType=article, longId=200296, objectId=bd47200296fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd47200296fe, replyNumber=0, likeNumber=57, createdTime=2021-02-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd47200296fe, moduleTitle=Lancet：Vosoritide治疗儿童软骨发育不良III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd47200296fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653181, encodeId=6e3e165318175, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Nat Med：新冠mRNA疫苗在我国的I期临床结果发布, objectType=article, longId=210762, objectId=889a210e62d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=889a210e62d3, replyNumber=0, likeNumber=47, createdTime=2021-08-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=889a210e62d3, moduleTitle=Nat Med：新冠mRNA疫苗在我国的I期临床结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=889a210e62d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

拜耳启动Elinzanetant III期临床研发项目OASIS，用于治疗更年期血管舒缩症状

2022-07-03

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

国药新冠疫苗国内上市申请获受理，III期临床仍在继续

2021-07-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验

2021-06-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Xerava（eravacycline）治疗复杂腹腔内感染：即将开展中国III期临床试验

2020-12-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

IkT-148009治疗帕金森，I期临床试验已正式开始

2021-11-02

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

晚期卵巢癌的治疗取得新进展，GEN-1在I / II期临床中取得喜人结果！

2021-11-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Nat Med：严重肥胖和代谢综合征患者的粪便微生物移植II期临床试验

2022-01-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

TC-210治疗难治性间皮素阳性实体瘤：I/II期临床试验取得积极结果

2021-01-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验

2021-07-18

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：TSLP单抗Tezepelumab治疗严重不受控制哮喘III期临床研究获得成功

2022-03-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

患者招募：吡咯替尼联合沙利度胺治疗HER2突变型非小细胞肺癌的单臂、开放、前瞻性II期临床研究

2021-08-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

HIV口服“疫苗”时代到来！默沙东口服长效新药开展III期临床

2021-04-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

REVTx-99治疗COVID-19：即将开展I期临床研究

2021-09-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

强生新冠疫苗进入III期临床试验，大选前疫苗出炉有望吗？

2020-12-18

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

以治愈艾滋病为目标！FDA批准美国基因技术公司（AGT）推进HIV治愈计划的I期临床

2021-01-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：Sotorasib治疗KRASp.G12C突变晚期非小细胞肺癌II期临床数据喜人

2021-06-10

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

强生单剂新冠疫苗综合有效率达66%，康希诺继续推进Ad5-nCoV的III期临床试验

2021-02-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期

2021-03-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet：Vosoritide治疗儿童软骨发育不良III期临床获得成功

2021-02-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Nat Med：新冠mRNA疫苗在我国的I期临床结果发布

2021-08-12

科室
- - 订阅+
  - 更多科室
工具
服务